Secukinumab and ixekizumab are current therapies for PsA and AS; therefore, we investigated the clinical efficacy of Ab-IPL-IL-17 in preclinical murine models of arthritis and ex vivo analysis from tissues of patients with RA or IBD. The gene discussed is IL17A; the disease is inflammatory bowel disease.